Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Publications

Biophysical interactions between components of the tumor microenvironment promote metastasis.

Vasilaki D. et al, (2021), Biophys Rev, 13, 339 - 357

The clinical landscape for AAV gene therapies.

Kuzmin DA. et al, (2021), Nat Rev Drug Discov, 20, 173 - 174

Evaluation of the Response of HOS and Saos-2 Osteosarcoma Cell Lines When Exposed to Different Sizes and Concentrations of Silver Nanoparticles.

Michalakis K. et al, (2021), Biomed Res Int, 2021

Pattern Recognition Receptor Polymorphisms as Predictors of Oxaliplatin Benefit in Colorectal Cancer.

Gray V. et al, (2019), J Natl Cancer Inst, 111, 828 - 836

Association analyses identify 31 new risk loci for colorectal cancer susceptibility.

Law PJ. et al, (2019), Nat Commun, 10

Mutation burden and other molecular markers of prognosis in colorectal cancer treated with curative intent: results from the QUASAR 2 clinical trial and an Australian community-based series.

Domingo E. et al, (2018), Lancet Gastroenterol Hepatol, 3, 635 - 643

The value of additional bevacizumab in patients with high-risk stroma-high colon cancer. A study within the QUASAR2 trial, an open-label randomized phase 3 trial.

Huijbers A. et al, (2018), J Surg Oncol, 117, 1043 - 1048

Prognostic markers for colorectal cancer: estimating ploidy and stroma.

Danielsen HE. et al, (2018), Ann Oncol, 29, 616 - 623

Pharmacoproteomic characterisation of human colon and rectal cancer.

Frejno M. et al, (2017), Mol Syst Biol, 13

Adjuvant capecitabine plus bevacizumab versus capecitabine alone in patients with colorectal cancer (QUASAR 2): an open-label, randomised phase 3 trial.

Kerr RS. et al, (2016), Lancet Oncol, 17, 1543 - 1557

Association of the OPRM1 Variant rs1799971 (A118G) with Non-Specific Liability to Substance Dependence in a Collaborative de novo Meta-Analysis of European-Ancestry Cohorts.

Schwantes-An T-H. et al, (2016), Behav Genet, 46, 151 - 169

Differential Efficacy of Nicotine Replacement Among Overweight and Obese Women Smokers.

Strong DR. et al, (2015), Nicotine Tob Res, 17, 855 - 861

The Predictive Role of ERCC1 Status in Oxaliplatin Based Neoadjuvant Therapy for Metastatic Colorectal Cancer (mCRC) to the Liver.

Geva R. et al, (2015), Cancer Invest, 33, 89 - 97

A candidate gene study of capecitabine-related toxicity in colorectal cancer identifies new toxicity variants at DPYD and a putative role for ENOSF1 rather than TYMS.

Rosmarin D. et al, (2015), Gut, 64, 111 - 120

Investigating the possible causal association of smoking with depression and anxiety using Mendelian randomisation meta-analysis: the CARTA consortium.

Taylor AE. et al, (2014), BMJ Open, 4

Genetic markers of toxicity from capecitabine and other fluorouracil-based regimens: investigation in the QUASAR2 study, systematic review, and meta-analysis.

Rosmarin D. et al, (2014), J Clin Oncol, 32, 1031 - 1039

Evaluation of PIK3CA mutation as a predictor of benefit from nonsteroidal anti-inflammatory drug therapy in colorectal cancer.

Domingo E. et al, (2013), J Clin Oncol, 31, 4297 - 4305

Weight change over eight years in relation to alcohol consumption in a cohort of continuing smokers and quitters.

Lycett D. et al, (2011), Nicotine Tob Res, 13, 1149 - 1154

Determinants of the rate of nicotine metabolism and effects on smoking behavior.

Johnstone E. et al, (2006), Clin Pharmacol Ther, 80, 319 - 330

Smoking cessation, weight gain, and DRD4 -521 genotype.

Munafò MR. et al, (2006), Am J Med Genet B Neuropsychiatr Genet, 141B, 398 - 402

Load More